Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paliperidone: quo vadis?

L Citrome1

  • 1Department of Psychiatry, New York University School of Medicine, and the Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA. citrome@nki.rfmh.org

International Journal of Clinical Practice
|March 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjunctive cariprazine for the treatment of major depressive disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Journal of affective disorders·2024
Same author

Use of a novel study insight analytics (SIA) methodology to improve PANSS data quality and signal detection in a global clinical trial in schizophrenia.

Schizophrenia research·2024
Same author

Goodbye Physicians' Desk Reference, hello Prescribers' Desk Reference!

International journal of clinical practice·2017
Same author

Food for thought: do you ask about eating?

International journal of clinical practice·2016
Same author

Rosacea and dementia: relative vs. absolute effect sizes.

International journal of clinical practice·2016
Same author

More inclusive bipolar mixed depression definition by permitting overlapping and non-overlapping mood elevation symptoms.

Acta psychiatrica Scandinavica·2016
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Paliperidone, an extended-release medication, effectively treats schizophrenia by demonstrating superior efficacy compared to placebo. However, potential side effects and cost concerns may impact its widespread clinical adoption.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Paliperidone is the active metabolite of risperidone and was approved for schizophrenia treatment in 2006.
  • It is also under investigation for bipolar mania.
  • Paliperidone is an extended-release oral formulation.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of paliperidone in treating schizophrenia.
  • To assess its effectiveness in relapse prevention.
  • To review safety data in elderly schizophrenia patients.

Main Methods:

  • Conducted three 6-week pivotal clinical trials of paliperidone extended-release (3-15 mg daily).
  • Performed an online literature search of PubMed and ClinicalTrials.gov for paliperidone and 9-hydroxy-risperidone.

Related Experiment Videos

  • Examined poster presentations from scientific meetings in 2006.

    • Main Results:

    • Paliperidone demonstrated superior efficacy over placebo in acute schizophrenia treatment.
    • Favorable tolerability was observed, with exceptions including prolactin elevation and dose-related extrapyramidal effects.
    • A relapse prevention study confirmed paliperidone's superiority over placebo in maintaining response.

    Conclusions:

    • Paliperidone is an effective treatment for acute schizophrenia and relapse prevention.
    • Potential side effects and the cost relative to generic risperidone may limit its use.
    • Further comparative studies with other second-generation antipsychotics are needed.